Avalo Therapeutics Files 8-K

Ticker: AVTX · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1534120

Avalo Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAvalo Therapeutics, INC. (AVTX)
Form Type8-K
Filed DateOct 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, corporate-update

Related Tickers: AVLO

TL;DR

AVLO filed an 8-K on Oct 8th, mostly procedural stuff, no major news yet.

AI Summary

On October 8, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific new financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing serves as an official notification to the SEC and investors about significant company events or financial updates, ensuring transparency in public trading.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently increases or decreases risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Avalo Therapeutics, Inc.?

The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting "Other Events" and "Financial Statements and Exhibits" as of October 8, 2024.

What is Avalo Therapeutics, Inc.'s state of incorporation and principal executive office location?

Avalo Therapeutics, Inc. is incorporated in Delaware and its principal executive offices are located at 540 Gaither Road, Suite 400, Rockville, Maryland 20850.

What is the Commission File Number and IRS Employer Identification No. for Avalo Therapeutics, Inc.?

The Commission File Number is 001-37590 and the IRS Employer Identification No. is 45-0705648.

When was Avalo Therapeutics, Inc. formerly known as Cerecor Inc.?

The company was formerly known as Cerecor Inc. prior to a name change on November 2, 2011.

Does this filing indicate any specific new business developments or financial results for Avalo Therapeutics?

The provided excerpt of the 8-K filing indicates the report covers "Other Events" and "Financial Statements and Exhibits" but does not detail specific new business developments or financial results within the excerpt itself.

Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-10-08 07:13:49

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 8, 2024, Avalo Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Company's Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. On October 8, 2024, the Company posted on its website an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated October 8 , 2024. 99.2 Investor Presentation. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: October 8, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing